Top-News
Pharmazeutika Japan

Daiichi Sankyo News

Aktie
WKN:  A0F57T ISIN:  JP3475350009 US-Symbol:  DSKYF
31,81 €
-0,34 €
-1,06%
15:36:16 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
1,92 Mrd.
Marktkapitalisierung *
63,50 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nikkei 225
IR-Website
zur Website
*Stand: 23.09.2023

Unternehmensmeldungen

18.01.21 - DGAP
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
DGAP-News: ViGeneron GmbH / Key word(s): Agreement ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy ...
30.07.18 - DGAP
Glycotope GmbH: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
DGAP-​Media / 30.07.2018 / 09:00
13.10.16 - ots
Daiichi Sankyo Announces New Data to be Presented at the ...
Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-​effectiveness of LIXIANA® (edoxaban) Munich ...
13.10.16 - ots
Daiichi Sankyo kündigt das kooperatives ...
Daiichi Sankyo kündigt das kooperatives Arzneimittelforschungsprogramm "TaNeDS Europe 2017" an Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (nachstehend ...
24.03.16 - ots
Daiichi Sankyo to Present Findings From New Subgroup ...
Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-​Daily LIXIANA® (edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session Munich ...
17.02.16 - ots
Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance ...
Daiichi Sankyo Launches Once-​Daily LIXIANA? Sales Alliance in Europe Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced ...
13.10.15 - ots
Daiichi Sankyo Partners With World Thrombosis Day to Promote ...
Daiichi Sankyo Partners With World Thrombosis Day to Promote Awareness of Venous Thromboembolism and Atrial Fibrillation, Helping to Reduce Preventable Deaths Munich ...
25.06.15 - ots
Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) Approved in ...
Daiichi Sankyo's Once-​Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT ...
18.06.15 - ots
Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to ...
Daiichi Sankyo Initiates Hokusai-​VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer Tokyo (ots/PRNewswire) - ...
24.04.15 - ots
Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Receives ...
Daiichi Sankyo's Once-​Daily Lixiana® (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-​Valvular Atrial Fibrillation and for the ...
15.04.15 - ots
Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for ...
Daiichi Sankyo's Once-​Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-​Valvular Atrial Fibrillation and for the Treatment and ...
03.09.14 - ots
Daiichi Sankyo öffnet kollaboratives ...
Daiichi Sankyo öffnet kollaboratives Arzneimittelforschungsprogramm TaNeDS in Europa für weitere Länder Tokio (ots/PRNewswire) - Daiichi Sankyo Company Limited (Tokioter ...
02.04.14 - ots
Daiichi Sankyo extends the PREFER in AF patient registry to ...
Daiichi Sankyo extends the PREFER in AF patient registry to provide additional insights into the long-term management of patients with atrial fibrillation Munich, Germany ...
29.07.13 - ots
Daiichi Sankyo erweitert sein gemeinsames ...
Daiichi Sankyo erweitert sein gemeinsames Arzneimittelforschungsprogramm auf Deutschland, die Schweiz und Österreich Tokio (ots/PRNewswire) - Daiichi Sankyo Company, ...
25.04.13 - ots
Perosphere and Daiichi Sankyo Enter into a Clinical Trial ...
Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, ...
10.09.12 - ots
Martin Hesse wird neuer Finanzvorstand von Daiichi Sankyo ...
Martin Hesse wird neuer Finanzvorstand von Daiichi Sankyo Europe / Der Pharmamanager tritt am 1. Oktober die Nachfolge von Max Schöner an (BILD) München (ots) - - ...
21.05.12 - ots
ArQule und Daiichi Sankyo geben den abschluss der ...
ArQule und Daiichi Sankyo geben den abschluss der patientenrekrutierung in phase 3 der klinischen studie von tivantinib gegen nicht-​kleinzelligen lungenkrebs bekannt Woburn, ...
17.05.12 - ots
World Hypertension Day 2012: Daiichi Sankyo Europe Announces ...
World Hypertension Day 2012: Daiichi Sankyo Europe Announces Patient Website Dedicated to Hypertension Munich (ots/PRNewswire) - **Not be used by UK media** To mark this ...
07.05.12 - ots
Daiichi Sankyo und Coherus BioSciences gründen strategische ...
Daiichi Sankyo und Coherus BioSciences gr\xFCnden strategische Zusammenarbeitzur Entwicklung und Vermarktung von bio\xE4hnlichen Kandidaten Redwood City, Kalifornien ...
28.10.11 - ots
Daiichi Sankyo und The Medicines Company vereinbaren ...
Daiichi Sankyo und The Medicines Company vereinbaren Vertriebskooperation f\xFCr Deutschland M\xFCnchen (ots) - Daiichi Sankyo und The Medicines Company (Deutschland) ...

Newssuche

Videos

newspaper
08:45 Uhr
Technical Trading: Sojabohnen im saisonalen Trend
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »